15.98

0.38% 0.06

After Hours: 15.98

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $15.98, with a volume of 363.44K. It is up +0.38% in the last 24 hours and down -2.20% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Previous Close:

$15.92

Open:

$15.84

24h Volume:

363.44K

Relative Volume:

0.70

Market Cap:

$926.47M

Revenue:

Net Income/Loss:

$-153.16M

P/E Ratio:

-4.7418

EPS:

-3.37

Net Cash Flow:

$-134.48M

1W Performance:

-5.56%

1M Performance:

-2.20%

6M Performance:

-43.63%

1Y Performance:

+61.09%

1-Day Range:

$15.15

$16.00

1-Week Range:

$15.15

$16.79

52-Week Range:

$7.64

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

CGEM's Discussions on Twitter

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

07:16 AM

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan

07:16 AM

02:11 AM

Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com

02:11 AM

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan

Nov 04, 2024

Nov 03, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat

Nov 03, 2024

Oct 30, 2024

FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat

Oct 30, 2024

Oct 24, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 22, 2024

Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Oct 22, 2024

SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 22, 2024

Oct 20, 2024

cullinan oncology, inc. Earnings dates - RTTNews

Oct 20, 2024

Oct 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat

Oct 18, 2024

Oct 17, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat

Oct 17, 2024

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Oct 17, 2024

Oct 16, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat

Oct 16, 2024

Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 16, 2024

Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan

Oct 16, 2024

Oct 11, 2024

How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News

Oct 11, 2024